Difference between revisions of "Quizartinib (Vanflyta)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
m |
||
Line 8: | Line 8: | ||
==Also known as== | ==Also known as== | ||
− | ASP2689 | + | *'''Code name:''' ASP2689 |
[[Category:Drug index]] | [[Category:Drug index]] | ||
− | [[Category: | + | [[Category:Mutation-specific medications]] |
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
Revision as of 01:06, 1 December 2017
Mechanism of action
FLT3 inhibitor
Preliminary data
Acute myeloid leukemia
- Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013 Oct 10;31(29):3681-7. Epub 2013 Sep 3. link to original article PubMed
- Abstract: Jorge E. Cortes, Alexander E Perl, Hervé Dombret, Sabine Kayser, Björn Steffen, Philippe Rousselot, Giovanni Martinelli, Elihu H. Estey, Alan K Burnett, Guy Gammon, Denise Trone, Eugen Leo, and Mark J. Levis Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia Blood (ASH Annual Meeting Abstracts), Nov 2012; 120: 48. link to abstract
Also known as
- Code name: ASP2689